We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byGeorge York
Modified over 6 years ago
Study flow diagram BB=blockers; HTN=hypertension; RCT=randomized controlled trial Bangalore S. et al. Am J Cardiol. 2007;100:1254-62
Clinical trials comparing ß-blockers with placebo or diuretics Bangalore S. et al. Am J Cardiol. 2007;100:1254-62
Blood pressure response: ß-blockers versus placebo or diuretics
Bangalore S. et al. Am J Cardiol. 2007;100:1254-62 Clinical trials comparing ß-blockers with nondiuretic antihypertensive agents
Bangalore S. et al. Am J Cardiol. 2007;100:1254-62 Blood pressure response: ß-blockers versus nondiuretic antihypertensive agents
Bangalore S. et al. Am J Cardiol. 2007;100:1254-62 Effect of ß-blockers on the risk for new-onset DM when compared to nondiuretic antihypertensive agents (CCBs, ACE inhibitors [ACEi], and ARBs)
Bangalore S. et al. Am J Cardiol. 2007;100:1254-62 Effect of different ß-blocker types on the risk for new-onset DM compared with other agents
Bangalore S. et al. Am J Cardiol. 2007;100:1254-62 Meta-regression analysis
Bangalore S. et al. Am J Cardiol. 2007;100:1254-62 RR for new-onset DM (NODM) as a function of systolic blood pressure (SBP) difference between ß-blockers and nondiuretic antihypertensive agents
Bangalore S. et al. Am J Cardiol. 2007;100:1254-62 RR for new-onset DM as a function of baseline fasting blood glucose levels
Bangalore S. et al. Am J Cardiol. 2007;100:1254-62 RR for new-onset DM as a function of baseline BMI
Bangalore S. et al. Am J Cardiol. 2007;100:1254-62 RR for new-onset DM as a function of length of follow-up
Bangalore S. et al. Am J Cardiol. 2007;100:1254-62 ß-blockers for primary hypertension: pathogenesis for increased risk. BP=blood pressure SM=smooth muscle
11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.
Resistant hypertension increases patients’ cardiovascular risk 30% of all treated patients develop resistant hypertension [1-5]. Resistant hypertension.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
חזק בהגנה לבבית Valsartan in Heart Failure
NHANES III Prevalence of Hypertension* According to BMI
HYPERTENSION in ADPKD Sabine Karam M.D.. Introduction ADPKD is the most common life-threatening single-gene disease It affects over 12 million people.
Hypertension Diagnosis and Treatment Based on JNC 7 – published in 2003 Goal: BP
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
The concept of Diabetes & CV risk: A lifetime risk challenge
Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.
1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
Randomized, double-blind, multicenter, controlled trial.
1 The Study of Trandolapril- verapamil And insulin Resistance STAR determined whether glycaemic control was maintained to a greater degree by an RAS inhibitor/non-DHP.
Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,
Sattar N, et al. Lancet 2010;375: Flow diagram of literature search to identify randomised placebo-controlled and standard care-controlled statin.
The TRial Of Preventing HYpertension (TROPHY) TROPHY.
Impact of Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker on Development of Glucose Intolerance and New-onset Diabetes Mellitus.
© 2021 SlidePlayer.com Inc. All rights reserved.